Construction and Evaluation of the Toxoplasma gondii DNA vaccine targeting DEC-205
Construction and Evaluation of the Toxoplasma gondii DNA vaccine targeting DEC-205
复制标题
弓形虫 DNA 疫苗 DEC-205 的构建与评价
DOI：
10.29261/pakvetj/2022.020
复制
发表时间：
2022-01-01
影响因子：
2.3
通讯作者：
Yin, Guangwen
中科院分区：
文献类型：
--
作者：
Chen, Rong;Peng, Jia jia;Yin, Guangwen
弓形虫病是由弓形虫（Toxoplasma gondii，T.弓形虫）仍然是一个严重的公共卫生问题。近年来，研究表明，靶向树突状细胞（DCs）的抗原有望增强机体对病原体和肿瘤的免疫应答。本研究构建并评价了一种新的T.弓形虫主要表面抗原SAG 1的基础上，gondii和针对小鼠DEC 205的抗体单链片段可变区（scFv），DEC 205是在DC和其它细胞的表面上表达的内吞受体。体外试验表达编码蛋白，分析细胞免疫和体液免疫应答，评价疫苗的保护效果。我们的研究结果表明，编码DEC-205 scFv与SAG 1融合的质粒显著增强了SAG 1特异性免疫应答，DC靶向可以诱导Th 1型免疫应答，这通过高水平的IFN-γ证明，IL-2和IgG 2a。因此，我们在这项研究中表明，DEC-205可以用于开发有效的T。弓形虫疫苗
Toxoplasmosis, caused by Toxoplasma gondii (T. gondii), remains a significant public health problem. Recently, it has been shown that the antigens targeting the dendritic cells (DCs) is a promising way to enhance the immune responses against pathogens and tumors. In this study, we constructed and evaluated a new DNA vaccine of T. gondii, based on the major surface antigen SAG1 of T. gondii and an antibody single-chain fragment variable (scFv) directed against the mouse DEC 205, an endocytic receptor expressed on the surface of DCs and other cells. The constructs were tested in vitro to express the encoded proteins, then the cellular and humoral immune responses were analyzed, and the protective efficacy of the vaccine was evaluated. Our results showed that the plasmid encoding the fusion of DEC-205 scFv with SAG1 significantly enhanced the SAG1-specific immune response and DC targeting could elicit the Th1 type immune response, evidenced by the high level of IFN-??, IL-2 and IgG2a. Therefore, we showed evidence in this research that DEC-205 can be exploited in developing an effective T. gondii vaccine.